Trim Therapeutics SA
Trim Therapeutics reported total assets of €1.50m at the end of the 2025 financial year (annual accounts filed with the NBB on 27 May 2026).
By total assets for 2025, Trim Therapeutics ranks in the top half of the 993 companies in its sector (NACE 7210) in Belgium that filed accounts for that financial year. Largest companies in the sector →
The score of Trim Therapeutics shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Accounts of the company itself (not consolidated).
Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Trim Therapeutics's annual accounts
| 2025 | |
|---|---|
| Net result | −€2.92m |
| Equity | −€2.81m |
| Cash | €1.39m |
| EBITDA | −628,116 € |
| Total assets | €1.50m |
Filed annual accounts
- Year ended 31 Dec 2025filed on 27 May 2026
Trim Therapeutics's financial analysis
- Solvency-187.5%sector median: 60.4%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Trim Therapeutics
Trim Therapeutics's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 1011.963.287
- VAT number
- BE1011963287
- Peppol
- Registered · 0208:1011963287 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 26 Jul 2024
- Registered office
- 9051 Ghent
- Latest accounts
- 2025 · filed on 27 May 2026
- Activity
- Research and experimental development on biotechnology (NACE 72101)
Trim Therapeutics (SA) has been based in Ghent since 2024, active in: research and experimental development on biotechnology. For 2025, it reports a net loss of €2.92m and equity of −€2.81m; its revenue is not published. Its solvency stands at -187.5%, below the median of its sector (60.4%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Trim Therapeutics
Companies in the same business, of comparable size and area, outside its group.
- NanoBiotech Research and experimental development on natural sciences and engineering Diepenbeek · balance sheet 1,834 €
- Novalix Belgium Research and experimental development on natural sciences and engineering Braine-l'Alleud · balance sheet €1.64m
- Matthys Charlotte Research and experimental development on natural sciences and engineering Aalter · balance sheet €1.65m
- Eilc Solar 21 Research and experimental development on natural sciences and engineering Herentals · balance sheet €1.32m
- E-Proteins Research and experimental development on natural sciences and engineering Gembloux · balance sheet €1.71m
- Bio INX Research and experimental development on natural sciences and engineering Ghent · balance sheet €1.24m
- Otorino Research and experimental development on natural sciences and engineering Waterloo · balance sheet €1.86m
- Hougardy Nicolas SRL Research and experimental development on natural sciences and engineering Habay · balance sheet €1.20m
Frequently asked questions about Trim Therapeutics
What is the revenue of Trim Therapeutics?
Trim Therapeutics files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Trim Therapeutics?
In Belgium, the VAT number is the company number prefixed with BE: BE1011963287 for Trim Therapeutics, if the company is VAT-registered. Its company number (CBE) is 1011.963.287.
Where is the registered office of Trim Therapeutics?
According to the CBE register, the registered office of Trim Therapeutics is in 9051 Ghent.
What is the equity of Trim Therapeutics?
At the close of the 2025 financial year, the equity of Trim Therapeutics amounts to -2,814,249 €, a solvency of -187.5% of total assets.
Who manages Trim Therapeutics?
The register lists 4 active mandates at Trim Therapeutics. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
How large is Trim Therapeutics within its sector?
By total assets for 2025, Trim Therapeutics ranks in the top half of the 993 companies in its sector (NACE 7210) in Belgium that filed accounts for that financial year.
The full file of Trim Therapeutics
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →